RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS. (12th June 2019) - Jagadeesh, D.